From Camouflet
If you've already done the reading — talked to your doctor, scoured dispensary menus, maybe even dug through threads on forums like FuckCombustion before it went dark — you don't need a glossary that explains what a cannabinoid is. What you need is a technically honest breakdown of how CBD and THC actually behave, what the research genuinely supports (and what it doesn't), how delivery method changes everything, and how to make a rational decision about ratios when you're managing a real condition or chasing a specific effect. That's what this is.
CBD and THC — What They Actually Are (Beyond the Basics)
Both CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol) are phytocannabinoids — plant-derived compounds that interact with the human endocannabinoid system (ECS). But the way they interact is fundamentally different, and that difference explains almost everything about their respective effects profiles.
THC is a partial agonist at CB1 receptors, which are densely distributed in the brain — particularly in the hippocampus, basal ganglia, cerebellum, and prefrontal cortex. When THC binds CB1, it mimics the endogenous ligand anandamide, producing the cascade of psychoactive effects users recognize: altered time perception, heightened sensory input, increased appetite, and at higher doses, anxiety or paranoia. CB1 activity also drives much of THC's analgesic and antiemetic action.
CBD does not bind meaningfully to CB1 or CB2 receptors. Instead, it acts as a negative allosteric modulator of CB1 — it physically changes the receptor's shape, reducing THC's ability to bind. Beyond that, CBD interacts with TRPV1 (the vanilloid receptor involved in pain and inflammation), 5-HT1A serotonin receptors (relevant to anxiety and depression), GPR55, and it inhibits the FAAH enzyme that breaks down anandamide. This isn't the same mechanism as THC. CBD is working on a different set of targets, which is why "it's all cannabis" is a grossly incomplete framing.
The practical upshot: THC gets you high because it activates CB1 directly. CBD doesn't get you high, and it actively reduces THC's psychoactivity. This is the mechanistic basis for ratio-based cannabis medicine.
How CBD and THC Interact: The Entourage Effect and Ratio Science
The entourage effect — the idea that cannabinoids and terpenes work better together than in isolation — is often treated as either gospel or pseudoscience depending on who's talking. The truth sits in the middle. There's legitimate evidence that CBD modulates THC's adverse effects (anxiety, psychosis-like symptoms, short-term memory impairment), and that certain terpenes like myrcene, linalool, and beta-caryophyllene contribute to the sedative or anxiolytic character of specific cultivars. What's less supported is the maximalist version of entourage theory that claims any isolate is categorically inferior to full-spectrum material for all applications.
What ratio science does give us is a practical framework. A 1:1 CBD-to-THC ratio tends to produce a milder psychoactive experience with enhanced analgesic properties — a combination that works well for pain patients who can tolerate some intoxication. High-CBD, low-THC ratios (20:1, 25:1) are used by patients who need therapeutic benefit without cognitive disruption — pediatric seizure patients, PTSD sufferers who can't function impaired, daytime users managing chronic conditions. High-THC dominant products remain what most recreational users seek and what many pain and nausea patients find most effective.
Terpenes layer onto this: a high-myrcene indica-dominant cultivar with a 1:1 ratio will feel meaningfully different from a high-limonene sativa-dominant with identical cannabinoid numbers. Cannabis terpenes and cannabinoids together create the actual clinical and experiential fingerprint of a product — which is why lab sheets that only report THC and CBD percentages are incomplete consumer information.
Medical Use Cases — What the Research Actually Supports
The state of cannabis medical research has historically been a disaster — not because cannabis doesn't have medical applications, but because Schedule I classification in the US (and similar restrictions internationally) made rigorous clinical research nearly impossible for decades. One FC community member put it well in a thread from that era: if all science were run the way marijuana research was run, creationists would control paleontology. That regulatory bias has slowly eroded, and what's emerged is a body of evidence that's genuinely useful when read honestly.
Epilepsy: The strongest and most replicated evidence for CBD specifically. Epidiolex (pharmaceutical-grade CBD isolate) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome. Earlier, anecdotal reports — including accounts of children whose seizures were dramatically reduced by high-CBD, low-THC cannabis extracts — were the catalyst for significant policy changes in multiple US states. The mechanism likely involves CBD's modulation of sodium channels and GABA pathways, distinct from its ECS activity.
Chronic pain: This is where the CBD vs THC picture gets complicated. THC has the stronger evidence base for nociceptive and neuropathic pain — it's an active analgesic via CB1. CBD's pain-related effects appear to work more through anti-inflammatory mechanisms (TRPV1, adenosine) and as a modulator of THC's effect duration. Combinations tend to outperform either alone in patient-reported outcomes, though head-to-head RCT data is still sparse. The practical evidence from medical patient communities is that 1:1 and 2:1 CBD:THC ratios are frequently preferred for chronic pain because they extend effect duration and reduce anxiety side effects from THC.
PTSD: THC is the more relevant cannabinoid here. Research from NYU, MAPS, and Israeli military studies suggests THC reduces REM sleep disturbances and helps suppress fear memory reconsolidation — both core PTSD mechanisms. CBD's contribution in this context is less clear, though its anxiolytic properties may reduce daytime hyperarousal. The challenge for PTSD patients is that THC's dose-response curve for anxiety is steeply nonlinear: low doses reduce anxiety, high doses can amplify it.
Nausea and appetite: THC's antiemetic effects via CB1 are well-established — Marinol (synthetic THC) was FDA-approved for chemotherapy-related nausea in 1985. Whole-plant products with the full terpene and minor cannabinoid profile tend to work faster and at lower doses than isolated THC, consistent with entourage effect arguments.
Diabetes: Preliminary but interesting. CBD has shown anti-inflammatory effects in pancreatic tissue in animal models, and some epidemiological data suggests cannabis users have lower fasting insulin and smaller waist circumference. This research is early and should not be the basis for altering any diabetes management protocol without medical supervision.
High-CBD, Low-THC Cannabis — Who Needs It and Why
The mainstream conversation around high CBD, low THC cannabis was transformed by pediatric epilepsy cases — children who had exhausted conventional pharmaceutical options, whose families were moving to Colorado or California specifically to access high-CBD cultivars like Charlotte's Web. That story was not anecdote; it was the leading edge of a verifiable clinical phenomenon that eventually produced Epidiolex.
Beyond pediatric epilepsy, the high-CBD, low-THC profile serves a distinct patient population: people who need to remain cognitively functional during treatment. This includes patients managing autoimmune conditions with inflammatory components, people using cannabis for anxiety who find THC counterproductive, older patients new to cannabis who are sensitive to psychoactivity, and professionals who need daytime symptom relief without impairment. It also includes people tapering off benzodiazepines or opioids who need therapeutic support without adding a new cognitive burden.
A 20:1 or 25:1 CBD:THC ratio — common in purpose-bred high-CBD cultivars and many CO2 extracts — delivers therapeutically relevant CBD doses with THC levels low enough (typically under 1% of total cannabinoids) that most users report no perceptible psychoactivity. The micro-dose of THC still present may contribute to the entourage effect without producing intoxication at these ratios.
Vaporizing CBD and THC — How Delivery Method Changes the Experience
This is where the technical details matter enormously and where the FC community accumulated years of practical knowledge that most clinical literature ignores entirely.
The fundamental difference between vaporizing and smoking cannabis is combustion. Smoking produces a chemical reaction that destroys a significant fraction of cannabinoids and terpenes while generating polyaromatic hydrocarbons, benzene, carbon monoxide, and other combustion byproducts. Research has consistently shown that marijuana smoking is not significantly linked to chronic obstructive pulmonary disease in the way tobacco is — but that finding doesn't mean the combustion byproducts are inert. It means frequent cannabis smokers don't develop COPD at the same rate as tobacco smokers, partly because of consumption volume differences and possibly because of bronchodilatory effects of THC itself. The combustion products are still there.
Vaporizing at controlled temperatures — typically 170–230°C (338–446°F) for dry herb — produces cannabinoid-rich vapor without combustion. Different temperature targets unlock different cannabinoid and terpene profiles:
- 170–185°C: THC begins to vaporize, light terpenes (myrcene, limonene, linalool) are active. Clear-headed, cerebral effect. CBD vaporizes minimally at this range.
- 185–200°C: CBD begins to vaporize meaningfully (boiling point ~160–180°C, but effective extraction requires higher airpath temperatures). More complete cannabinoid extraction. This is the standard working range for most sessions.
- 200–230°C: Heavier terpenes (humulene, caryophyllene), CBN (from THC degradation), and remaining cannabinoids. More sedative character. Efficiency drops and vapor quality decreases at the upper end.
For CBD-dominant material, this temperature control is particularly important. CBD has a higher boiling point than THC, which means low-temp sessions that work well for THC-dominant flower will underextract CBD. High-CBD cultivars often benefit from slightly higher temperature settings to fully activate the cannabinoid content.
The device matters. Convection heating — where hot air passes through the material rather than the bowl itself heating — produces more even extraction and more accurate temperature delivery than conduction. For medical patients using high-CBD, low-THC cannabis where dosing consistency matters, a quality convection vaporizer is not a luxury; it's a functional requirement. Camouflet's lineup is built entirely around convection heating for exactly this reason. The Fuji — Camouflet's flagship portable — uses an all-glass-and-ceramic airpath with no plastic anywhere in the vapor pathway, which matters when you're vaporizing medicine multiple times a day. For patients who need desktop precision, the Inductor V2 delivers induction-based heating with extremely stable temperature control, useful for dialing in exact extraction profiles for specific CBD:THC ratios. Budget-conscious patients should look at the Convector V2, which Camouflet offers through a Pay What You Can program specifically because access to clean vaporization shouldn't be a financial barrier.
Bioavailability comparison: inhaled cannabis (vaporized or smoked) delivers cannabinoids to the bloodstream within minutes, with peak plasma levels at 3–10 minutes and effects lasting 1–3 hours. Oral/edible delivery produces slower onset (30–120 minutes), longer duration (4–8 hours), and converts some THC to 11-hydroxy-THC, a more potent psychoactive metabolite — which is why edibles hit differently than inhaled cannabis at equivalent doses. For titration and dose control, inhalation via vaporization is generally preferred by medical users who need to adjust effects in real time.
Cannabis, Anxiety, and Mental Health — Separating Facts from Fear
The anxiety question is one of the most practically relevant and most honestly complicated in cannabis medicine. The FC community's thread on whether marijuana causes anxiety even when not high was getting at something real: cannabis doesn't just affect you while you're high.
THC's relationship with anxiety is dose-dependent and nonlinear. At low doses, THC typically produces anxiolytic effects — reduced worry, social ease, reduced physiological stress response. At high doses, particularly in inexperienced users or in high-stress contexts, THC can produce acute anxiety, paranoia, and in rare cases, transient psychosis-like symptoms. This is reproducible in controlled studies. The CB1 receptors THC activates are abundant in the amygdala, which is the brain's primary fear-processing center — and the direction of CB1 modulation on amygdala activity is highly dose and context dependent.
CBD counteracts this at the mechanistic level. As a CB1 negative allosteric modulator, CBD reduces THC's ability to over-activate those amygdala receptors. CBD also directly activates 5-HT1A serotonin receptors, the same target as buspirone (an anti-anxiety medication), which has independent anxiolytic effects. The clinical implication: cannabis for anxiety works best with meaningful CBD content, and THC-dominant products can make anxiety worse in susceptible users, especially at high doses.
The schizophrenia question deserves honest treatment. There is a genuine epidemiological association between heavy adolescent THC use and increased risk of psychosis in people with genetic predisposition (particularly those with certain COMT gene variants). This association is real, even if it has been grotesquely exaggerated by prohibition-era advocacy. The key words are "heavy," "adolescent," and "predisposition." The risk for adult users without genetic vulnerability is not clearly established, and the absolute risk increase, even in high-risk groups, is modest. High-CBD products, given CBD's antipsychotic properties (it was shown to perform comparably to amisulpride in one schizophrenia trial), are likely a safer choice for anyone with personal or family history of psychotic disorders who wants to use cannabis therapeutically.
Regarding post-high anxiety: some regular THC users do experience increased baseline anxiety between sessions, possibly related to downregulation of CB1 receptors with chronic use. This normalizes within days to weeks of abstinence. It's not a permanent change, but it's worth knowing about.
Concentrates, Extracts, and Cannabinoid Purity — What to Watch Out For
The FC community flagged this issue early: some Oregon CO2 extracts were found to contain elevated levels of pulegone, a possible carcinogen that occurs naturally in certain cannabis cultivars but can concentrate during extraction. This isn't an argument against concentrates — it's an argument for understanding what's in them.
CO2 extraction, when done properly at supercritical pressures, produces clean, full-spectrum extracts that preserve cannabinoids and terpenes without residual solvents. The problem is that "CO2 extracted" on a label tells you about the method, not the quality control. Subcritical CO2 extraction better preserves terpene profiles; supercritical is more efficient for cannabinoid yield. Neither method eliminates naturally occurring compounds like pulegone if they're in the source material.
Butane hash oil (BHO), live resin, and rosin each have different profiles. Solventless rosin (heat-pressed from fresh or cured flower) has become the preferred option among purity-conscious concentrate users because there are no residual solvents to test for. The tradeoff is yield efficiency and cost. For medical patients using concentrates daily, third-party testing for residual solvents, heavy metals, and pesticides is not optional — it's basic quality assurance.
Hash and kief — mechanical separations of trichomes — sit in a different category. No solvent risk, no extraction chemistry, but also no standardization of potency. A well-made dry-sieve hash can range from 40–70% total cannabinoids; quality bubble hash from 50–80%. Knowing your source material's cannabinoid profile is the starting point for any reliable dosing protocol.
Concentrates in vaporizers require different hardware than dry herb. Dedicated concentrate vaporizers, or devices with compatible inserts, typically operate at higher temperatures. For hash specifically, devices like the Ceramo XL — built from pure black zirconia ceramic with no O-rings and an ultra-high-flow stem — handle the higher temperatures required for hash and concentrates without off-gassing or flavor contamination from rubber or plastic components.
Cannabis as a Substitute — Exit Drug Evidence and Prescription Alternatives
The "gateway drug" narrative has been the dominant public framing of cannabis for decades. The evidence running in the opposite direction — cannabis as an exit drug or substitute — is now substantial enough that dismissing it is no longer scientifically defensible.
Several high-quality studies have found associations between medical cannabis access and reduced opioid prescriptions, reduced opioid overdose deaths, and self-reported opioid substitution. A 2014 JAMA Internal Medicine paper found that states with medical marijuana laws had 25% lower opioid overdose mortality rates than states without — a finding that has been updated and debated but not overturned. Patient surveys consistently show 30–40% of medical cannabis patients report substituting cannabis for prescription opioids, benzodiazepines, or alcohol.
The mechanism is plausible: endocannabinoid and opioid systems interact extensively at the spinal cord level, and cannabinoids can produce analgesia through pathways that don't create the same physical dependence profile as opioids. For anxiety and sleep, cannabis (particularly high-CBD products) may reduce the perceived need for benzodiazepines, which carry significant dependence and withdrawal risk of their own.
This doesn't mean cannabis is without dependence potential — cannabis use disorder is real and affects approximately 9% of users who ever try cannabis, rising to around 17% among those who start in adolescence. But the withdrawal syndrome (irritability, sleep disruption, appetite changes lasting 1–2 weeks) is not physiologically dangerous in the way opioid or benzodiazepine withdrawal is. The harm profile comparison matters for clinical decision-making.
Legal Access and What It Means for Getting the Right Product
Legal status directly determines what you can access and at what quality. The patchwork of regulations across US states, Canadian provinces, and international jurisdictions creates dramatically different consumer protection environments.
In fully legal adult-use or medical markets with mandatory testing (California, Colorado, Canada's federally licensed producers), you can access lab-verified products with accurate cannabinoid ratios and testing for contaminants. In states with medical-only programs, access to specific CBD:THC ratios may be limited and prices are typically higher. In prohibition states, you're sourcing from unregulated supply with no quality controls whatsoever — which matters enormously if you're using cannabis for epilepsy or another serious medical condition where product consistency is clinically important.
Canada's federally licensed system, which commercialized and expanded on the old Health Canada medical program, has produced a standardized testing environment — though critics note that commercialization has prioritized certain formats and price points over the product diversity that medical patients need. Home cultivation rights for personal medical use have been a meaningful alternative for patients who can grow specific cultivars for their therapeutic needs.
For patients in regions where only hemp-derived CBD is legally available (under 0.3% THC by dry weight), the product landscape is heavily unregulated. A 2019 Penn Medicine study found that nearly 70% of CBD products sold online were mislabeled — containing either more or less CBD than stated. This is not a minor quality issue for a patient using CBD for seizure control. Third-party certificates of analysis from ISO-certified labs should be non-negotiable for any CBD product purchased in unregulated markets.
How to Choose Your CBD-to-THC Ratio Based on Your Goals
There is no universal optimal ratio. The practical starting framework, informed by both clinical research and community experience, looks like this:
- Seizure disorders (especially pediatric): High CBD, very low THC — 20:1 or higher. Pharmaceutical CBD (Epidiolex) if accessible; rigorously tested full-spectrum high-CBD extract if not. Vaporization is often not appropriate for pediatric patients; oil-based oral delivery is standard.
- Chronic pain: 1:1 to 2:1 CBD:THC for daytime or moderate pain; higher THC ratios for breakthrough or severe pain when impairment is acceptable. Vaporized delivery for rapid onset; oral for sustained background relief.
- PTSD and sleep: THC-dominant products (1:5 CBD:THC or higher THC) for sleep disruption and nightmare suppression; CBD-forward products for daytime anxiety and hypervigilance. Session dose control is critical — THC's biphasic anxiety response makes titration important.
- General anxiety: CBD-dominant (5:1 to 20:1 CBD:THC) for anxious users who find THC activating; 1:1 for those who can tolerate mild psychoactivity. Cannabis for anxiety with high THC content is frequently counterproductive.
- Nausea and appetite stimulation: THC-dominant. CBD is not the relevant cannabinoid for these applications.
- Recreational use without anxiety: The traditional THC-dominant high, but CBD content even at 1:4 ratios noticeably smooths the experience and reduces paranoia risk. Many experienced users actively seek cultivars with some CBD content for exactly this reason.
For vaporizing any of these ratios in dry herb form, consistent convection heating gives you the most reliable cannabinoid extraction. If you're using cannabis medicinally and precision matters, the device you use is not incidental to your outcomes. A poorly designed conduction vaporizer running hot and inconsistent is extracting differently every session — which is fine for recreational use but genuinely problematic if you're titrating dose for seizure management or anxiety. The Convector XL V2 delivers convection-only heating with a large titanium-machined heater matrix that provides surface uniformity and fast heat-up — practical for medical patients who need consistent results from consistent hardware.
The Practical Truth About CBD and THC
The CBD-versus-THC framing is useful as a starting point but breaks down quickly in practice. These compounds are not enemies or competitors — they're tools with different mechanisms, different clinical targets, and different risk profiles, and they interact with each other in ways that can be deliberately leveraged for specific therapeutic goals.
What the research actually supports: CBD for epilepsy is proven; CBD and THC combinations for pain have strong patient-reported evidence and growing clinical support; THC for PTSD sleep disruption is mechanistically credible and clinically promising; the schizophrenia risk is real but limited to specific populations and use patterns; cannabis as an opioid substitute has meaningful epidemiological support. What the research doesn't support: the idea that CBD is universally safer than THC in all contexts (CBD inhibits drug metabolism enzymes and has real drug interactions), or that high THC is always the more effective medical option.
The most practically useful thing you can do, regardless of where you are in this — whether you're a medical patient, an experienced recreational user, or someone navigating between the two — is to understand your specific target, match your ratio to your mechanism, control your temperature when vaporizing, and demand third-party testing data from any extract product you're putting in your body. The days when accepting an unmarked baggie was the only option are mostly over. Use the access you have.